BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...

JPMorgan says that following Hindenburg Research’s short report on Carvana (CVNA), the key debates are now centered around four topics: Ally Financial (ALLY) partnership viability and new loan partner ...